Compare · NVS vs PHIO
NVS vs PHIO
Side-by-side comparison of Novartis AG (NVS) and Phio Pharmaceuticals Corp. (PHIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and PHIO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $305.69B, about 34058.3x PHIO ($9.0M).
- PHIO has been more active in the news (11 items in the past 4 weeks vs 5 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 1 for PHIO).
- Company
- Novartis AG
- Phio Pharmaceuticals Corp.
- Price
- -
- -
- Market cap
- $305.69B
- $9.0M
- 1M return
- +6.36%
- -
- 1Y return
- +21.79%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 11
- Recent ratings
- 25
- 1
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762, which targets the checkpoint protein PD-1 that prevent T cells from attacking various cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that prevent cancer cells from inactivating T cells and attack the cancer. It has collaboration with AgonOx, Inc. on clinical development of novel immunotherapy drugs targeting key regulators of the immune response to cancer. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank
Latest PHIO
- Amendment: SEC Form SCHEDULE 13G/A filed by Phio Pharmaceuticals Corp.
- Director Deming David H bought $9,823 worth of shares (12,000 units at $0.82), increasing direct ownership by 24% to 61,800 units (SEC Form 4)
- Director Deming David H bought $10,066 worth of shares (12,000 units at $0.84), increasing direct ownership by 32% to 49,800 units (SEC Form 4)
- Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
- Director Plott Ronald Todd bought $15,189 worth of shares (18,300 units at $0.83), increasing direct ownership by 44% to 60,300 units (SEC Form 4)
- Chairman, Pres. & CEO Bitterman Robert J bought $20,500 worth of shares (25,000 units at $0.82), increasing direct ownership by 3% to 789,871 units (SEC Form 4)
- Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
- Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
- SEC Form 10-Q filed by Phio Pharmaceuticals Corp.
- Phio Pharmaceuticals Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits